COVID-19 Nucleocapsid IgG Quantitative ELISA Assay Kit

$825.00

The COVID-19 Nucleocapsid IgG Quantitative ELISA Assay kit is designed, developed, and produced for the quantitative measurement of the human anti-COVID-19 IgG antibody in serum. This assay utilizes the microplate based enzyme immunoassay technique. This test is not the same as PCR or Rapid Test. The Coronavirus COVID-19 Quantitative IgG ELISA Assay Kit is for Research Use Only (RUO) in the USA, CE-Marked.

COVID-19 Nucleocapsid IgG Quantitative ELISA Assay Kit

COVID-19 Nucleocapsid IgG Quantitative ELISA Assay Kit was developed and manufactured in the US

Size: 1×96 wells
Sensitivity: 0.17 U/mL
Dynamic Range: 0.17-200 U/mL
Incubation Time
: 1.5 Hours
Sample Type: Serum
Species Sample: Human
Sample Size: 10 µL
Alternative Names: Serology, Coronavirus, COVID-19, Corona, Serological
RUO, CE-Marked

Controls Included


Cross Reactivity

Panels were studied with a minimum of eight confirmed disease state samples with this serology assay. No interference was observed for the following disease or infectious agents:

  • Anti-influenza A
  • Anti-influenza B
  • Hepatitis C (HCV)
  • Antinuclear Antibodies (ANA)
  • Respiratory Syncytial (RSV)

Assay Principle

The COVID-19 Nucleocapsid IgG Quantitative ELISA Assay kit is designed, developed, and produced for the quantitative measurement of the human anti-COVID-19 IgG antibody in serum. This assay utilizes the microplate based enzyme immunoassay technique.

Assay calibrators, controls, and 1:100 diluted human serum samples are added to the microtiter wells of a microplate that was coated with COVID-19 recombinant full length nucleocapsid protein. After the first incubation period, the unbound protein matrix is removed with a subsequent washing step. A horseradish peroxidase (HRP) labeled polyclonal goat anti-human IgG tracer antibody is added to each well. After an incubation period, an immunocomplex of “COVID-19 recombinant antigen – human anti-COVID-19 IgG antibody – HRP labeled anti-human IgG tracer antibody” is formed if there is specific coronavirus IgG antibody present in the tested specimen. The unbound tracer antibody is removed by the subsequent washing step. HRP-labeled anti-hIgG tracer antibody bound to the well is then incubated with a substrate solution in a timed reaction and then measured in a spectrophotometric microplate reader. The enzymatic activity of the tracer antibody bound to the anti-COVID-19 IgG on the wall of the microtiter well is proportional to the amount of the anti-COVID-19 IgG antibody level in the tested specimen.


Products Related to COVID-19 Nucleocapsid IgG Quantitative ELISA Assay Kit

Coronavirus COVID-19 IgG ELISA Assay Kit
Coronavirus COVID-19 IgM ELISA Assay Kit
Anti-SARS-CoV-2 S1 (RBD) IgG ELISA Assay
Anti-SARS-CoV-2 (S1, S2, N) IgG ELISA Assay Kit

Additional Information

Assay Background

2019 novel coronavirus (2019-nCoV or SARS-CoV-2 or COVID-19) is a single-stranded RNA coronavirus2. Comparisons of the genetic sequences of this virus have shown similarities to SARS-CoV and bat coronaviruses7. In humans, coronaviruses cause respiratory infections3. Coronaviruses are composed of several proteins including the spike (S), envelope (E), membrane (M), and nucleocapsid (N)4. Results suggest that the spike protein retains sufficient affinity to the Angiotensin converting enzyme 2 (ACE2) receptor to use it as a mechanism of cell entry6. Human to human transmission of coronaviruses is primarily thought to occur among close contacts via respiratory droplets generated by sneezing and coughing1. IgG is the most abundantly found immunoglobulin to be produced in response to an antigen and will be maintained in the body after initial exposure for long term response.


Package Inserts